| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $61K | — | -99.0% |
| SG&A Expense | $1.7M | — | -62.1% |
| Operating Income | -$1.8M | — | +83.1% |
| Net Income | -$1.6M | — | +81.9% |
| EPS (Basic) | -$0.14 | — | +90.1% |
| EPS (Diluted) | -$0.14 | — | +90.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.8M | -76.7% | -95.8% |
| Short-term Investments | $7.0M | — | — |
| Current Assets | $12.3M | +29.8% | -73.1% |
| Total Assets | $12.3M | +29.8% | -74.5% |
| Current Liabilities | $1.6M | -37.6% | -93.2% |
| Total Liabilities | $1.6M | -37.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.9M | — | +67.2% |
| Investing Cash Flow | -$7.0M | — | — |
| Financing Cash Flow | $4.1M | — | +3138.5% |
| -96.3% |
| Stockholders' Equity | $10.8M | +53.8% | +88.5% |